Concert receives FDA breakthrough status for CTP-543 in alopecia areata
There are currently no drugs approved by the FDA for the treatment of alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in
Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities globally, from Sanofi.
The EC approval allows using Lynparza as a maintenance treatment for adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed
On July 3, 2020, the Brazilian National Regulatory Agency, Anvisa, granted approval to a phase III clinical trial sponsored by Instituto Butantan to test efficacy and safety of